pharma · Multiple Myeloma · Ovarian Cancer · CASIF
CASI Pharmaceuticals
CASI Pharmaceuticals clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 601 Gateway Blvd, San Francisco, CA 94080, US
- Employees
- 44
- Programs
- 22
- Drugs
- 11
- Patents
- 2
CASI Pharmaceuticals projects
16 ClinicalTrials.gov programs sponsored by CASI Pharmaceuticals.
CASI Pharmaceuticals has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
2-methoxyestradiol
CASI Pharmaceuticals
Relapsed Multiple Myeloma
1 trial -
CID-103
CASI Pharmaceuticals
Chronic Immune Thrombocytopenia
1 trial -
ENMD-2076
CASI Pharmaceuticals
Advanced Adult Hepatocellular Carcinoma
1 trial -
ENMD-2076
CASI Pharmaceuticals
Ovarian Cancer
1 trial -
ENMD-2076
CASI Pharmaceuticals
Triple Negative Breast Cancer
1 trial -
ME-CLN-002
CASI Pharmaceuticals
Carcinoid Tumor
1 trial -
MKC-1
CASI Pharmaceuticals
Pancreatic Cancer
1 trial -
MKC-1
CASI Pharmaceuticals
Advanced Cancer
2 trials -
MKC-1
CASI Pharmaceuticals
Breast Cancer
1 trial -
MKC-1
CASI Pharmaceuticals
Ovarian Cancer
1 trial -
Panzem NCD
CASI Pharmaceuticals
Recurrent Glioblastoma Multiforme
1 trial -
Panzem Nanocrystal Colloidal Dispersion
CASI Pharmaceuticals
Recurrent Glioblastoma Multiforme
1 trial -
Panzem Nanocrystal Colloidal Dispersion (NCD)
CASI Pharmaceuticals
Ovarian Cancer
1 trial -
Panzem® NCD
CASI Pharmaceuticals
Metastatic Renal Cell Carcinoma
1 trial -
Panzem® NCD
CASI Pharmaceuticals
Prostate Cancer
1 trial -
recombinant human Angiostatin protein
CASI Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
1 trial
Frequently asked questions
How many clinical projects does CASI Pharmaceuticals have?
16 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.